Zoetis Inc. (NYSE:ZTS) Shares Purchased by Epoch Investment Partners Inc.

Epoch Investment Partners Inc. grew its stake in Zoetis Inc. (NYSE:ZTS) by 25.6% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,481,542 shares of the company’s stock after purchasing an additional 301,691 shares during the period. Zoetis makes up approximately 1.2% of Epoch Investment Partners Inc.’s portfolio, making the stock its 11th biggest holding. Epoch Investment Partners Inc. owned about 0.32% of Zoetis worth $256,840,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of ZTS. Vanguard Group Inc. boosted its holdings in shares of Zoetis by 1.0% in the first quarter. Vanguard Group Inc. now owns 40,749,571 shares of the company’s stock valued at $6,895,235,000 after acquiring an additional 414,605 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Zoetis by 31.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 13,716,681 shares of the company’s stock valued at $2,707,262,000 after buying an additional 3,244,074 shares in the last quarter. Capital World Investors grew its holdings in Zoetis by 0.6% during the fourth quarter. Capital World Investors now owns 9,064,158 shares of the company’s stock worth $1,788,988,000 after acquiring an additional 57,798 shares during the period. Bank of New York Mellon Corp lifted its holdings in Zoetis by 4.0% in the second quarter. Bank of New York Mellon Corp now owns 4,687,902 shares of the company’s stock valued at $812,695,000 after acquiring an additional 178,303 shares during the period. Finally, Capital Research Global Investors increased its holdings in shares of Zoetis by 2.3% in the 1st quarter. Capital Research Global Investors now owns 4,050,681 shares of the company’s stock valued at $685,416,000 after purchasing an additional 90,330 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on ZTS. Stifel Nicolaus increased their target price on shares of Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a report on Wednesday. BTIG Research upped their target price on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a report on Monday, August 12th. Argus upgraded shares of Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Finally, Piper Sandler lifted their target price on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. Nine equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Zoetis presently has an average rating of “Buy” and an average price target of $220.38.

Zoetis Stock Performance

Shares of ZTS opened at $192.64 on Friday. The company has a market capitalization of $87.90 billion, a price-to-earnings ratio of 37.12, a PEG ratio of 2.98 and a beta of 0.88. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.09 and a current ratio of 3.45. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $201.92. The company’s 50 day simple moving average is $184.70 and its 200 day simple moving average is $174.40.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.49 by $0.07. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The business had revenue of $2.36 billion for the quarter, compared to analysts’ expectations of $2.31 billion. During the same quarter last year, the firm earned $1.41 earnings per share. The business’s revenue was up 8.3% on a year-over-year basis. On average, sell-side analysts predict that Zoetis Inc. will post 5.84 EPS for the current year.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.